GLASGOW—Serum C-reactive protein (CRP) levels, a marker of systemic inflammation, are associated with residual urgency after medical treatment for benign prostatic hyperplasia (BPH), data show.
“The significant association between residual urgency and serum CRP in our study implies that chronic inflammation may play a role in the occurrence of residual urgency symptoms in BPH patients,” Taiwan researchers concluded.
Chun-Hou Liao, MD, of Cardinal Tien Hospital and Fu-Jen Catholic University in Taipei, and colleagues studied 205 men with clinical BPH, defined as a total prostate volume of 40 mL or greater, an International Prostate Symptom Score (IPSS) of 8 or higher, and a maximum flow rate (Qmax) below 12 mL/sec. All men had been on stable BPH medication for more than 12 months. Subjects had a mean serum CRP level of 0.24 mg/dL.
The investigators identified residual urgency in 90 patients (43.9%). Men with a CRP level of 0.3 mg/dL or higher (39 subjects) had a significant 8.2 times increased risk of residual urgency compared with men who had lower CRP levels (166 subjects), after adjusting for age, serum PSA level, and antimuscarinic use, according to findings reported at the International Continence Society annual meeting. Compared with subjects in the first quartile of CRP levels, those in the fourth quartile had a significant 12.9 times increased risk of urgency.
The authors also concluded that serum CRP level may be a diagnostic tool for predicting residual urgency in BPH patients.